Hematology

A prior resubmission in June 2022 was delayed with requests for additional durability and safety data.

Review top news and interview highlights from the week ending September 30, 2022.

Patients treated with the highest dose of MIC-Lx had lymphocyte reactivity against third-party cells but not stimulatory donor blood cells.

Of the 17 patients treated, 12 patients achieved a response, including 6 who achieved a complete response.

Rob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.

CTX-130 is being investigated in phase 1 studies for relapsed/refractory T or B-cell malignancies and renal cell carcinoma.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.

Bluebird bio’s ZYNTEGLO was the first gene therapy to be approved in the space in August 2022.

The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.

Review top news and interview highlights from the week ending September 23, 2022.

The FDA previously lifted its clinical hold of the AFFINE study in May 2022.

Interim data showed a 78% overall response rate and a 67% complete response rate.

Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The grant will specifically help support the trial’s treatment arm for patients with post-transplant acute myeloid leukemia with minimal residual disease.

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

Review top news and interview highlights from the week ending September 16, 2022.

A single-center study assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The gene therapy received a conditional marketing approval in the European Union in August 2022.

The announcement comes after positive top-line results in the ongoing KarMMa-3 study.

Among the 31 patients evaluable for efficacy analysis, ORR was 100%.

A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.